Results 61 to 70 of about 20,601 (250)

Alpha-adrenergic receptor agonists in terms of modern views on glaucoma monitoring and treatment [PDF]

Клиническая офтальмология, 2019
The article reviews historical aspects of direct and indirect (by reducing intraocular pressure (IOP)) neuroprotective effect of brimonidine in terms of modern views on glaucoma monitoring and treatment.
V.P. Erichev, S.Yu. Petrov, A.V. Volzhanin, D.M. Safonova, T.V. Yaremenko, S.A. Kazaryan   +5 more
doaj  

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

Multitarget Regulatory Mechanisms and Research Advances of Plant‐Derived Bioactive Ingredients in Hypertension Prevention and Management

Phytotherapy Research, EarlyView.
Schematic overview of the multi‐target and multi‐pathway mechanisms of PDBI in the prevention and management of hypertension. ABSTRACT Hypertension remains a major global risk factor for cardiovascular diseases, yet current treatments face challenges such as suboptimal blood pressure control and inadequate organ protection.
Qiqi Deng, Yonglin Zhang, Jing Pan, Jing Luo, Hualin Sun, Chaonian Li, Li Li   +6 more
wiley   +1 more source

Dexmedetomidine as an Adjuvant in Peripheral Nerve Block

Drug Design, Development and Therapy, 2023
Zheping Chen, Zhenzhen Liu, Chang Feng, Yanwu Jin, Xin Zhao Department of Anesthesiology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250012, People’s Republic of ChinaCorrespondence: Yanwu Jin; Xin Zhao, Email ...
Chen Z, Liu Z, Feng C, Jin Y, Zhao X
doaj  

Neurotrophic Signaling, Sleep Physiology, and Retinal Neuroprotection: Integrative Mechanisms and Therapeutic Implications for Glaucoma

Sensory Neuroscience, EarlyView.
Glaucoma is increasingly understood as a neurodegenerative disorder shaped by sleep and circadian physiology, not intraocular pressure alone. Sleep loss and obstructive sleep apnea suppress BDNF–TrkB neurotrophic signaling, impair sleep‐dependent glymphatic clearance, and trigger microglial neuroinflammation and vascular insult at the optic nerve head,
Karyme M. Alemán‐Villa, Emiliano Terán, Javier A. Magaña‐Gómez, Loranda Calderón‐Zamora, Beatriz K. De la Herrán‐Arita, Alberto K. De la Herrán‐Arita   +5 more
wiley   +1 more source

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

Small, EarlyView.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source

Barriers and facilitators to detoxification from opioid substitution treatment: A mixed‐methods systematic review

Addiction, EarlyView.
Abstract Background and aims Despite the well‐documented benefits of opioid substitution treatment (OST) in treating opioid dependence (OD), many people diagnosed with OD desire to live a drug‐free life. The transition to abstinence involves detoxification: a gradual dose reduction of OST to zero milligrams.
Amy Bagshaw, Suleyman Shah, India Olchefske, Louise M. Paterson, Mike J. Crawford, Anne Lingford‐Hughes   +5 more
wiley   +1 more source

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration (RISE‐AMD): Safety data

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan, Celine Lee, Kaweh Daniel Zohalinejad, Mads Odgaard Mæng, Nanna Würtz Fabrin, Sigurrós Jónsdóttir, Anne Kjærsgaard Hassing, Søren Kveiborg Yde, Charles C. Wykoff, Henrik Vorum, Yousif Subhi, Marie Ørskov, Lasse Jørgensen Cehofski   +12 more
wiley   +1 more source

Alpha2 agonists for sedation to produce better outcomes for adults with critical illness: a synopsis of the A2B RCT with cost-effectiveness and process evaluation

Health Technology Assessment
Parts of this abstract have been reproduced with permission from Walsh TS, Parker RA, Aitken LM, McKenzie CA, Emerson L, Boyd J, et al.; A2B Trial Investigators.
Timothy S Walsh, Richard A Parker, Leanne M Aitken, Lydia Emerson, Cathrine A McKenzie, Julia Boyd, Alix MacDonald, Gayle Beveridge, Annabel Giddings, David Hope, Sîan Irvine, Sharon Tuck, Nazir I Lone, Kalliopi Kydonaki, John Norrie, Benedict Creagh-Brown, Daniel F McAuley, Paul Dark, Matt P Wise, Anthony C Gordon, Gavin D Perkins, Michael C Reade, Bronagh Blackwood, Alasdair MacLullich, Robert Glen, Valerie J Page, Stephen Morris, Christopher J Weir,   +28 more
doaj   +1 more source